ReviewPharmaceuticals (Basel, Switzerland)2026
Pharmaceutical Compounding as a Pillar of Personalized Oncology: Current Applications, Emerging Technologies, and Future Perspectives.
Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Personalized oncology is transforming cancer care by tailoring therapeutic strategies to the molecular and clinical characteristics of individual patients. However, increasing treatment complexity, interpatient variability, and the growing use of advanced therapeutics challenge the limitations of standardized medicines. This review examines pharmaceutical compounding as a fundamental component enabling the delivery of individualized oncology treatments. A literature search was conducted in PubMed/MEDLINE, Scopus, and Web of Science, using a predefined search strategy detailed in the manuscript. This narrative review of the literature was conducted to evaluate the application of pharmaceutical compounding in modern oncology practice. The analysis includes immunotherapy, nanotechnology-based drug delivery systems, genomic-guided therapy, and combination treatment strategies. Emerging technologies, such as artificial intelligence, three-dimensional printing, and robotic compounding, were also assessed, alongside regulatory frameworks, safety challenges, and quality considerations. The main findings of this study show that compounded medications support individualized care through dose adjustment, modification of dosage forms, and exclusion of unsuitable excipients, particularly in pediatric oncology, rare cancers, and patients with specific needs. The magistral and officinal preparations help maintain continuity of care when commercial formulations are unavailable. In addition, technological advances are improving the precision, reproducibility, and safety of compounding processes, and pharmacists are centrally involved in the design, preparation, quality assurance, and regulatory oversight of these therapies. In conclusion, pharmaceutical compounding remains an essential component of personalized oncology, enabling patient-centered and adaptable treatment strategies. The expanding engagement of pharmacists, together with advances in technology and evolving regulatory frameworks, is essential to ensuring the safe and effective implementation of individualized therapies in oncology care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.